aTyr Pharma (NASDAQ:LIFE) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.
According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “
Other research analysts also recently issued research reports about the stock. ValuEngine downgraded shares of aTyr Pharma from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. JPMorgan Chase & Co. downgraded shares of aTyr Pharma from a “neutral” rating to an “underweight” rating in a research report on Wednesday, February 14th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. aTyr Pharma presently has an average rating of “Hold” and a consensus target price of $4.75.
Shares of LIFE stock opened at $2.90 on Wednesday. aTyr Pharma has a 52 week low of $2.30 and a 52 week high of $6.50. The stock has a market cap of $89.64, a price-to-earnings ratio of -1.43 and a beta of 3.54. The company has a debt-to-equity ratio of 0.17, a current ratio of 9.49 and a quick ratio of 9.49.
Several institutional investors and hedge funds have recently made changes to their positions in LIFE. Victory Capital Management Inc. bought a new position in shares of aTyr Pharma in the 3rd quarter valued at about $455,000. Dimensional Fund Advisors LP boosted its holdings in shares of aTyr Pharma by 44.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock worth $423,000 after buying an additional 25,676 shares during the period. Artal Group S.A. boosted its holdings in shares of aTyr Pharma by 100.0% during the 4th quarter. Artal Group S.A. now owns 500,000 shares of the biotechnology company’s stock worth $1,750,000 after buying an additional 250,000 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of aTyr Pharma by 143.2% during the 4th quarter. Renaissance Technologies LLC now owns 279,400 shares of the biotechnology company’s stock worth $978,000 after buying an additional 164,500 shares during the period. Finally, Deutsche Bank AG bought a new stake in shares of aTyr Pharma during the 4th quarter worth about $199,000. 58.65% of the stock is owned by institutional investors.
WARNING: This report was first published by Stock Observer and is owned by of Stock Observer. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.thestockobserver.com/2018/03/21/atyr-pharma-life-downgraded-by-zacks-investment-research-to-hold.html.
aTyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.